ACADIA Pharmaceuticals (NASDAQ:ACAD) Posts Earnings Results

05 Aug 2026, 00:56 by Danessa Lincoln · The Markets Daily

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12, FiscalAI reports. ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The business had revenue of $308.00 million for the quarter, compared to the consensus estimate of $295.51 million. During the same period in the previous year, the firm earned $0.16 EPS. The business’s revenue was up 16.4% on a year-over-year basis.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

Second-quarter revenue rose 17% to $308 million on an adjusted basis, driven by strong demand for both DAYBUE and NUPLAZID.
DAYBUE sales increased 30% to $125 million, with DAYBUE STIX adopted by approximately 40% of U.S. patients by quarter-end and helping bring discontinued patients back to treatment. ACADIA raised its 2026 DAYBUE guidance to $480 million–$510 million.
NUPLAZID sales grew 10% to $183 million, while new patient prescriptions rose 20% year over year. Management said the expanded field force is beginning to contribute and maintained its goal of approximately $1 billion in 2028 NUPLAZID sales.
DAYBUE received a positive CHMP opinion in Europe, with a European Commission decision expected by the end of the third quarter and a planned German launch in early fourth quarter. Management expects Europe to represent less than half of its $700 million 2028 DAYBUE sales target.
The key pipeline catalyst is the phase II RADIANT readout for remlifanserin in Alzheimer’s disease psychosis, now expected in September–October after enrollment of 363 patients. ACADIA has begun phase III screening, but the program remains dependent on demonstrating clinically meaningful efficacy and a supportive safety profile.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD stock traded up $1.54 during trading on Tuesday, reaching $27.15. The company’s stock had a trading volume of 2,437,594 shares, compared to its average volume of 1,425,453. The company has a market capitalization of $4.65 billion, a price-to-earnings ratio of 12.34, a P/E/G ratio of 17.76 and a beta of 0.81. The stock’s 50-day moving average price is $23.95 and its 200 day moving average price is $23.20. ACADIA Pharmaceuticals has a 1-year low of $19.69 and a 1-year high of $28.35.

Wall Street Analyst Weigh In

ACAD has been the subject of several research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, July 29th. Citigroup upped their price target on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Bank of America restated a “buy” rating and set a $14.50 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. HC Wainwright cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 30th. Finally, Canaccord Genuity Group boosted their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday, June 29th. Thirteen research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.31.

Get Our Latest Research Report on ACAD

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the transaction, the executive vice president owned 18,994 shares of the company’s stock, valued at $496,313.22. This trade represents a 46.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider James Kihara sold 5,401 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This trade represents a 18.06% decrease in their position. The disclosure for this sale is available in the SEC filing. 26.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ACAD. Meeder Asset Management Inc. acquired a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at about $26,000. Transamerica Financial Advisors LLC grew its position in shares of ACADIA Pharmaceuticals by 304.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 1,005 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of ACADIA Pharmaceuticals by 277.5% during the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 1,185 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of ACADIA Pharmaceuticals by 51.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,596 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 884 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in ACADIA Pharmaceuticals in the third quarter valued at approximately $93,000. 96.71% of the stock is owned by institutional investors and hedge funds.

About ACADIA Pharmaceuticals

(Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.